Medical/Pharmaceuticals
Medit Set to Launch a New Intraoral Scanner, Medit i900 classic
SEOUL, South Korea and NEWPORT BEACH, Calif., March 11, 2025 /PRNewswire/ --
Medit (www.medit.com
2025-03-11 15:00
3874
Harbour BioMed Appoints Dr. Ian Y. Liu as Global Head of Legal
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 10, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology, today announced ...
2025-03-11 08:00
2002
Harbour BioMed Appoints Michael D. Patten as Chief Strategy Officer
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 10, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology, today announced ...
2025-03-11 08:00
2071
Wingderm® Presents at the 2025 AAD Annual Meeting, Strengthening Its Presence in the North American Market
BEIJING, March 10, 2025 /PRNewswire/ -- Wingderm® once again participated in the 2025 AAD Annual Meeting, which was held inOrlando, Florida, from March 7 to 9. The American Academy of Dermatology is the largest, most influential, and most representative dermatologic association. During the event,...
2025-03-11 01:00
2597
Gan & Lee Pharmaceuticals Announced First Participant Dosed in the US Phase 2 Clinical Study of Bofanglutide (GZR18) Injection for Overweight or Obesity
BEIJING and BRIDGEWATER, N.J., March 10, 2025 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087) announced that the first participant has been successfully dosed in a Phase 2 clinical trial of bofanglutide (research code: GZR18) injection, a bi-weekly glucagon-...
2025-03-10 23:45
2604
Sunway Medical Centre named top Malaysian Hospital in Newsweek's World's Best Hospitals ranking
SUBANG JAYA, Malaysia, March 10, 2025 /PRNewswire/ -- Sunway Medical Centre,
Sunway City (SMC) has yet again ranked in the top 250 hospitals globally in the
latest Newsweek's World's Best Hospitals 2025 rankings.
2025-03-10 21:59
3861
World's First Large-Scale, Multicenter Prospective Study in Single-Reading Mammography Confirms Lunit AI Boosts Cancer Detection
Prospective study finds Lunit AI increases cancer detection by 13.8% in single-reader settings without raising recall rates, presenting a game-changing tool for countries relying on single-reader mammography screening SEOUL, South Korea, March 10, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a le...
2025-03-10 21:00
2637
Gleneagles Hospital Hong Kong pioneers transformative Histotripsy treatment for liver cancer in private sector in Asia
HONG KONG, March 10, 2025 /PRNewswire/ -- Gleneagles Hospital Hong Kong (Gleneagles) is excited to be the first private hospital inAsia to offer Histotripsy treatment, the transformative and non-invasive technology that uses high-intensity ultrasound waves to destroy tumours for liver cancer pati...
2025-03-10 20:30
2624
SPRIM Global Investments and OneIM Announce $300mn Joint Venture to Accelerate Clinical Trial Financing
SINGAPORE and NEW YORK, March 10, 2025 /PRNewswire/ -- SPRIM Global Investments ("SGI"), a global investment firm specializing in clinical-stage life sciences and pharma services based inSingapore, and One Investment Management ("OneIM"), a global alternative investment management firm, today ann...
2025-03-10 20:19
2697
Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) Approved for Marketing in Second Indication by NMPA for EGFRm NSCLC
CHENGDU, China, March 10, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, formerly SKB264/MK-2870) was approved ...
2025-03-10 19:22
2085
Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan
VALBY, Denmark, March 10, 2025 /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) inJapan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA). H. Lundbeck A/S (Lundbeck) a...
2025-03-10 16:57
2023
Doer Biologics Completes Enrollment of the Phase 2 Clinical Study of DR10624 for Treatment of Severe Hypertriglyceridemia
HANGZHOU, China, March 9, 2025 /PRNewswire/ -- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers,today announces that DR10624, its first-in-class (FIC), tri-specific agonist targeting...
2025-03-10 10:53
2115
RiboX Therapeutics Announces First Patient Dosed in Phase I/IIa Clinical Trial of RXRG001, the First Circular RNA Therapy for the Treatment of Radiation-Induced Xerostomia and Hyposalivation
PRINCETON, N.J., March 9, 2025 /PRNewswire/ -- RiboX Therapeutics Ltd. (RiboX), a pioneering biopharmaceutical company, focused on discovering and developing fully engineered circular RNA therapeutics, today announced that the first patient was dosed last week in its first-in-human (FIH) Phase I/...
2025-03-10 09:30
2492
China Telecom and Partners Innovate Together! 5G UAV Medical Delivery Network Wins Global Mobile Award
HONG KONG, March 10, 2025 /PRNewswire/ -- On March 5, during the 2025 Mobile World Congress (MWC25), the 5G UAV medical delivery network solution jointly developed by China Telecom, Hangzhou Antwork Network Technology andZhejiang University was awarded the Global Mobile Award (GLOMO Award) for "B...
2025-03-10 08:39
3256
AIM Vaccine's Iteratively Upgraded Diploid Rabies Vaccine Approved for Clinical Trials, Showing Significantly Higher Efficacy than Marketed Diploid Rabies Vaccines
HONG KONG, March 10, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement onMarch 9, 2025, the company's research and development of a diploid rabies vaccine has recently received the Clinical Trial Approval Notice from the National Medic...
2025-03-10 08:00
3680
U.S. FDA approves Celltrion's OMLYCLO® (omalizumab-igec) as the first and only biosimilar with interchangeability designation referencing XOLAIR®
* OMLYCLO® (omalizumab-igec) is the first and only omalizumab biosimilar approved by theFDA * Regulatory approval for interchangeability was supported by positive phase III data demonstrating comparable efficacy and safety profile with the reference product XOLAIR® (omalizumab)[1] * The ava...
2025-03-10 07:16
2908
Manulife Extends Strategic Partnership with CUHK Medical Centre to Include Histotripsy in its Holistic "Medical Professional Support Service"
Histotripsy is an FDA-approved technology that offers liver cancer patients a non-invasive, painless, and highly effective treatment option HONG KONG, March 7, 2025 /PRNewswire/ -- Manulife announced today the extension of its strategic partnership with CUHK Medical Centre (CUHKMC), originally e...
2025-03-07 16:32
2393
MWC 2025 | Huawei Showcases Scenario-based Solutions at MWC For Intelligent Healthcare
BARCELONA, Spain, March 7, 2025 /PRNewswire/ -- During the Mobile World Congress (MWC) 2025, Huawei held a global healthcare industry session themed Digital Intelligence Drives Inclusive Healthcare. Experts shared their latest strategies and practices in digital transformation and AI application ...
2025-03-07 16:09
3559
LEADING WITH HEART - The Women of PHKL Shaping the Future of Healthcare
KUALA LUMPUR, Malaysia, March 7, 2025 /PRNewswire/ -- Healthcare is more than science—it is compassion, resilience, and an unwavering commitment to healing. Behind every life saved and every family given hope, there are extraordinary individuals who dedicate themselves to the well-being of others...
2025-03-07 13:50
4241
Akeso Announces The Publication of Its Phase III Clinical Trial Results for Ivonescimab in Head-to-Head Comparison with Pembrolizumab in The Lancet
HONG KONG, March 7, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company")is excited to announce that the groundbreaking results of the Phase III clinical study (HARMONi-2/AK112-303) of its first-in-class PD-1/VEGF bispecific antibody, ivonescimab, as a monotherapy compared to pemb...
2025-03-07 13:03
2251
Week's Top Stories
Most Reposted
Visa partners with Laufey to spread the magic of travel in Asia Pacific; to be Official Payment Partner for Laufey: A Matter of Time Tour
[Picked up by 310 media titles]
2026-03-04 12:35
TelkomMetra Streamlines Business Portfolio, AdMedika Group Poised to Enter a New Growth Phase on Regional Level Under Fullerton Health
[Picked up by 295 media titles]
2026-03-09 21:36
Progress Software Highlights Load Balancing as a Strategic Imperative for APAC Digital Infrastructure Resilience
[Picked up by 290 media titles]
2026-03-10 09:00
COL and NASDAQ-Listed BeLive Holdings Unveil World's First "Microdrama in a Box" in Headline Hong Kong FILMART 2026 Launch
[Picked up by 287 media titles]
2026-03-05 17:14
Gene Solutions Announces Strategic Entry into Türkiye with Robust Real-World Evidence at the 2nd International Hereditary Cancers Congress 2026
[Picked up by 267 media titles]
2026-03-04 10:00
Most Read
Visa partners with Laufey to spread the magic of travel in Asia Pacific; to be Official Payment Partner for Laufey: A Matter of Time Tour
2026-03-04 12:35
7582
